Welcome To The Mannkind HUB On AGORACOM

Edit this title from the Fast Facts Section

Free
Message: Re: MannKind’s Afrezza Likely to Fail AFFINITY 1 Phase III Trial

I agree, thats what the big push for the independent monitoring group was for.

That being said, wouldn't the increase in the use of TI push the hypoglycemia events up to being on part with the RAA?

See Table 4/5:

http://www.mannkindcorp.com/Collateral/Documents/English-US/12-2009_EASD_009_Poster_982.pdf

I guess this is the trade off between aggressively treating A1C vs. aggressively reduing hypoglycemia events.

Share
New Message
Please login to post a reply